Picture of Thermogenesis Holdings logo

THMO — Thermogenesis Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyHighly SpeculativeMicro Cap

ThermoGenesis Holdings: Rises on COVID-19 treatment plans

** Shares of cell-based therapy company  THMO.O  rise 15.9%
to $9.40
    ** THMO is developing convalescent plasma and antibody
therapeutic approaches against COVID-19 in collaboration with
joint venture partner ImmuneCyte Life Sciences Inc  urn:newsml:reuters.com:*:nPn4TGr9Pa
    ** ImmuneCyte has acquired intellectual property of four
antibody drug candidates to treat COVID-19 virus
    ** THMO and ImmuneCyte are using their combined technology
to identify antibodies from blood of individuals who have
recovered from the disease, which could then be used as a
potential treatment - THMO
    ** Including session's gain, shares up ~114% YTD



 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))

Recent news on Thermogenesis Holdings

See all news